VR Logo

Context Therapeutics Inc. (CNTX) download report


Healthcare | Biotechnology & Pharma Research

Context Therapeutics Inc. (CNTX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States.

IPO Date: 20-Oct-2021

Co-Founder, Pres, CEO & Director: Mr. Martin A. Lehr

CFO & Treasurer: Ms. Jennifer Minai-Azary

Listing: NASDAQ: CNTX

Country: United States

Headquarters: Philadelphia, PA

Website: https://www.contexttherapeutics.com

Key Facts

Market cap: $33.53 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-13.00 Mln

Cash: $45.73 Mln

Total Debt: $0.12 Mln

Insider's Holding: 10.46%

Liquidity: Low

52 Week range: $1.27 - 252.00

Shares outstanding: 15,966,100

6 Years Aggregate:

  • CFO: $-65.59 Mln
  • EBITDA: $-8.50 Mln
  • Net Profit: $-72.48 Mln

Stock Performance

Time Period Context Therapeutics (CNTX) S&P BSE Sensex S&P Small-Cap 600
YTD-14.38-8.71-17.92
1 month11.10-3.11-7.88
3 months1.22-7.30-13.56
1 Year-98.820.48-17.16
3 Years-83.1310.346.95
5 Years-68.0111.436.30
10 Years-54.4312.1010.29
As on 28-Jun-2022
Year Context Therapeutics (CNTX) S&P Small-Cap 600 S&P BSE Sensex
2021-98.7725.2721.99
2020-35.509.5715.75
201916,800.0020.8614.38
2018-99.56-9.705.87
2017-36.0011.7327.91
2016-94.8524.741.95